InsiderTrades

Form 4 for TARS Tarsus Pharmaceuticals, Inc.

Accepted 2023-03-17 00:00:00 ET · period of report 2023-03-15 · accession 0001209191-23-019883 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-03-17 2023-03-16 TARS Whitfield Dianne C. CHRO S - Sale+OE $13.43 -313 12.9K -2% -$4,204
D 2023-03-17 2023-03-15 TARS Whitfield Dianne C. CHRO M - OptEx — +4,462 13.2K +51% —
D 2023-03-17 2023-03-15 TARS Whitfield Dianne C. CHRO M - OptEx $0.00 -4,462 13.4K -25% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-03-16 S D 313 $13.43 12,872 D — —
2 Common Common Stock 2023-03-15 M A 4,462 — 13,185 D — — (F1) The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
3 Derivative Restricted Stock Units 2023-03-15 M D 4,462 $0.00 13,388 D — · — to — 4,462 Common Stock (F3) Each RSU represents a contingent right to receive one share of the Company's common stock. (F4) RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.